Overview
Tomas Jurcek practices practicing medicine in Brno, Czech Republic.
Mr. Jurcek is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML) and Leukemia.
He is actively involved in clinical research, co-authoring 24 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Tomas Jurcek
Is Tomas Jurcek a top-rated expert for Chronic Myelogenous Leukemia (CML)?
MediFind is an objective health platform that identifies experts based on real-world data. Tomas Jurcek is classified as an Distinguished expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Tomas Jurcek participate in research or clinical trials?
Yes. Tomas Jurcek has published 24 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Tomas Jurcek's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Chronic Myelogenous Leukemia (CML)Mr. Jurcek isDistinguished. Learn about Chronic Myelogenous Leukemia (CML).
- Advanced
- LeukemiaMr. Jurcek isAdvanced. Learn about Leukemia.